VVOS News and Press, Vivos Therapeutics Inc. From 11/15/21

Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and Positive Study Results Management to Host Co...

Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 pre...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”), will be presenting at the upcoming Q4 Virtual Investor Summit. The sum...

HIGHLANDS RANCH, Colo., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep a...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, today announced that it...

HIGHLANDS RANCH, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients s...

A new study has discovered a link between triglycerides and obstructive sleep apnea ("OSA"). Triglycerides are a type of lipid in the blood that gives energy to an individual�s body. High triglyceride levels raise an individual�s risk of pancreatitis, strokes and heart attac...

The National Institutes of Health estimates that about 25 million individuals in America suffer from obstructive sleep apnea. Obstructive sleep apnea is a common sleep disorder that causes an individual’s breathing to start and stop while they’re asleep. The disorder affects ...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, today announced that its chairman...

HIGHLANDS RANCH, Colo., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients s...